GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » YoY EPS Growth

Zai Lab (HKSE:09688) YoY EPS Growth : 20.46% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Zai Lab's YoY EPS Growth for the quarter that ended in Mar. 2025 was 20.46%.

Zai Lab's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was HK$-0.31.


Zai Lab YoY EPS Growth Historical Data

The historical data trend for Zai Lab's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab YoY EPS Growth Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.71 -118.47 39.58 23.68 26.05

Zai Lab Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 38.61 43.07 20.36 20.46

Zai Lab YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Zai Lab's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-2.021--2.733)/ | -2.733 |
=26.05 %

Zai Lab's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(-0.311--0.391)/ | -0.391 |
=20.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zai Lab YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Zai Lab's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Executives
Fmr Llc 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Du Ying 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Janus Henderson Group Plc 2102 Investment manager
Ubs Group Ag 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines